J4 ›› 2011, Vol. 37 ›› Issue (3): 529-533.

• 基础研究 • 上一篇    下一篇

氟替卡松/沙美特罗对哮喘患者外周血单个核细胞中辅助性T细胞亚群及气道炎症的影响

侯松萍1,李立1,于倩2   

  1. 1.吉林大学中日联谊医院呼吸科|吉林 长春 130033;2.吉林大学中日联谊医院药剂科|吉林 长春 130033
  • 收稿日期:2011-01-05 出版日期:2011-05-28 发布日期:2011-05-28
  • 通讯作者: 侯松萍(Tel:0431-84995860,E-mail:hosping@163.com) E-mail:hosping@163.com
  • 作者简介:侯松萍(1962-)|女|黑龙江省齐齐哈尔市人|主任医师|医学博士|主要从事气道的免疫应答与炎症的研究。
  • 基金资助:

    中华医学会临床医学慢性呼吸道疾病科研专项基金资助课题(07010040012)

Effects of fluticasone/salmeterol on peripheral blood TH subsets and airway inflammation in patients with asthma

HOU Song-ping1|LI Li1|YU Qian2    

  1. 1. |Department of Respiratory Medicine|China-Japan Union Hospital,Jilin University|Changchun 130033|China;2. Department of Pharmacy,China-Japan Union Hospital,Jilin University|Changchun 130033|China
  • Received:2011-01-05 Online:2011-05-28 Published:2011-05-28

摘要:

目的:探讨氟替卡松/沙美特罗对哮喘患者外周血单个核细胞中辅助性T细胞亚群(Th)及气道炎症的影响,为其临床治疗哮喘提供理论依据。方法:13例慢性持续期中度哮喘患者,给予氟替卡松/沙美特罗连续治疗1.5和3.0个月。检测治疗前后外周血Th亚群(Th1、Th2和Th3)、血清细胞因子及IgE水平,观察诱导痰炎症细胞的变化和临床疗效。结果:氟替卡松/沙美特罗治疗1.5个月时,与治疗前比较,哮喘患者外周血Th3百分数增加、Th2百分数减少(P<0.05),转化生长因子β(TGF-β)、白细胞介素4(IL-4)无明显变化(P>0.05);痰嗜酸细胞(eos)百分比明显降低(P<0.01),血eos及痰中性粒细胞百分比无明显变化;呼气峰流速值 (PEF)、哮喘控制测试(ACT)评分明显增加,PEF变异率明显降低(P<0.01),每日急救药物使用无明显减少。治疗3个月时,与治疗前比较,Th1、Th1/Th2、Th3明显增加,Th2明显减少(P<0.05或P<0.01);IL-4、TGF-β明显降低(P<0.05),干扰素γ(IFN-γ)明显增加(P<0.05);IgE含量无明显变化(P>0.05);血eos、痰eos及痰中性粒细胞均明显降低(P<0.01);PEF、ACT评分明显增加,PEF变异率明显降低(P<0.01),每日急救药物使用次数明显减少(P<0.01)。治疗3.0个月与治疗1.5个月时比较,PEF变异率继续降低、ACT评分继续增加(P<0.01)。结论: 氟替卡松/沙美特罗能提高哮喘患者外周血Th3数量,纠正Th1/Th2失衡,减轻气道炎症和临床症状,且随治疗时间延长,效果进一步提高。

关键词: 支气管哮喘;辅助性T细胞亚群;细胞因子;气道炎症;氟替卡松;沙美特罗

Abstract:

Abstract:Objective  To explore the effects of fluticasone/salmeterol  on T helper cell(Th) subsets in peripheral blood  and airway inflammation in patients with asthma and provide a theoretical basis for their clinical application in treatment of asthma. Methods  13 patients with chronic persistent moderate asthma received  250 μg fluticasone/50 μg salmeterol inhalation (twice daily) for 1.5 and 3.0 months. The changes of peripheral Th subsets and the levels of their cytokines and IgE in serum were detected,the inflammatory cells in induced sputum and the clinical effects in patients with asthma treated by fluticasone/salmeterol were observed.Results  Compared with before treatment,after treatment of  1.5 months  in patients with asthma:the percentage of Th3 was increased(P<0.05),the percentage of  Th2 was decreased(P<0.05),the TGF-β and IL-4 had no significant change  in the peripheral blood(P>0.05);the eosinophils(eos) in sputum was significantly decreased(P<0.01),the eos  in blood and neutrophils in sputum had no significant change;the PEF and ACT scores were  increased(P<0.01),the PEF variability was decreased (P<0.01), the use frequency of rescue medications for daily had no significant decrease; after treatment of  3.0 months:the Th1,Th1/Th2 and Th3 were increased,the Th2 was decreased(P<0.05 or P<0.01);the IL-4 and TGF-β  were decreased(P<0.05),the IFN-γ was increased (P<0.05);the level of IgE had no significant change;the  eos in blood,eos  and neutrophils in sputum were decreased(P<0.01);the PEF and ACT scores were  increased,the PEF variability was decreased (P<0.01),the use frequency of rescue medications for daily was decreased(P<0.01);and the PEF variability was continuously decreased,the ACT were continuously increased (P<0.01)after treatment of  3.0 months compared after treatment of 1.5 months.Conclusion  Fluticasone/salmeterol can increase the numbers of  Th3 cells in peripheral blood of patients with asthma,correcte the imbalances of Th1/Th2 ratio ,reduce asthmatic airway inflammation and clinical symptoms in a time-dependent manner.

Key words: bronchial asthma; , T helper cell subsets;cytokine;airway inflammation; fluticasone;salmeterol

中图分类号: 

  • R562.25